Compare Stocks: KZIA, CAPR, EIKN, and EBS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$6.59 -4.2%	$7.93	$2.96 ▼ $40.37	$400M	0.61	3.75 million shs	2.51 million shs
EBS Emergent Biosolutions	$6.90 -0.2%	$6.05	$4.36 ▼ $14.06	$354.30M	2.28	1.14 million shs	761,078 shs
EIKN Eikon Therapeutics	$7.01 +4.3%	$9.48	$6.45 ▼ $17.40	$363.99M	N/A	638,873 shs	595,509 shs
KZIA Novogen	$6.79 -15.5%	$11.54	$4.86 ▼ $17.40	$104.27M	2.26	247,808 shs	825,335 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	-4.22%	-18.64%	-25.20%	-65.53%	-1.64%
EBS Emergent Biosolutions	-0.72%	-2.60%	+8.48%	-10.16%	-24.36%
EIKN Eikon Therapeutics	+4.32%	-7.03%	-25.11%	-29.55%	+700,999,900.00%
KZIA Novogen	-15.55%	-26.91%	-39.16%	-48.25%	-2.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$6.59 -4.2%	$7.93	$2.96 ▼ $40.37	$400M	0.61	3.75 million shs	2.51 million shs
EBS Emergent Biosolutions	$6.90 -0.2%	$6.05	$4.36 ▼ $14.06	$354.30M	2.28	1.14 million shs	761,078 shs
EIKN Eikon Therapeutics	$7.01 +4.3%	$9.48	$6.45 ▼ $17.40	$363.99M	N/A	638,873 shs	595,509 shs
KZIA Novogen	$6.79 -15.5%	$11.54	$4.86 ▼ $17.40	$104.27M	2.26	247,808 shs	825,335 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	-4.22%	-18.64%	-25.20%	-65.53%	-1.64%
EBS Emergent Biosolutions	-0.72%	-2.60%	+8.48%	-10.16%	-24.36%
EIKN Eikon Therapeutics	+4.32%	-7.03%	-25.11%	-29.55%	+700,999,900.00%
KZIA Novogen	-15.55%	-26.91%	-39.16%	-48.25%	-2.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	2.27	Hold	$30.25	359.03% Upside
EBS Emergent Biosolutions	2.17	Hold	$10.00	45.03% Upside
EIKN Eikon Therapeutics	2.50	Moderate Buy	$25.00	256.63% Upside
KZIA Novogen	2.67	Moderate Buy	$28.80	324.15% Upside

Current Analyst Ratings Breakdown

Latest KZIA, CAPR, EIKN, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/17/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/16/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/11/2026	CAPR Capricor Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/10/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$40.00
9/9/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
9/7/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Overweight
9/1/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$34.00 ➝ $40.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$22.27M	17.20	N/A	N/A	$5.53 per share	1.19
EBS Emergent Biosolutions	$742.90M	0.48	$3.65 per share	1.89	$9.95 per share	0.69
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	$42K	2,096.66	N/A	N/A	($5.34) per share	-1.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	9.32	N/A	-22.95%	16.35%	6.17%	11/4/2026 (Estimated)
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest KZIA, CAPR, EIKN, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	CAPR Capricor Therapeutics	-$0.1278	N/A	N/A	N/A	$41.71 million	N/A
11/4/2026	Q3 2026	EBS Emergent Biosolutions	-$0.37	N/A	N/A	N/A	$123.22 million	N/A
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	7.35	7.35
EBS Emergent Biosolutions	1.70	5.42	2.95
EIKN Eikon Therapeutics	N/A	9.89	9.89
KZIA Novogen	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
EBS Emergent Biosolutions	78.40%
EIKN Eikon Therapeutics	N/A
KZIA Novogen	30.89%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	9.20%
EBS Emergent Biosolutions	6.00%
EIKN Eikon Therapeutics	N/A
KZIA Novogen	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	231	58.14 million	52.79 million	Optionable
EBS Emergent Biosolutions	900	51.27 million	48.20 million	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
KZIA Novogen	6	12.97 million	12.84 million	No Data

KZIA, CAPR, EIKN, and EBS Headlines

Recent News About These Companies

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

September 22, 2026 | prnewswire.com

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

September 9, 2026 | prnewswire.com

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript

September 4, 2026 | seekingalpha.com

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

September 1, 2026 | prnewswire.com

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

September 1, 2026 | prnewswire.com

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

August 31, 2026 | prnewswire.com

Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data

August 31, 2026 | seekingalpha.com

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

August 28, 2026 | prnewswire.com

Kazia Therapeutics Limited Announces Proposed Public Offering

August 27, 2026 | prnewswire.com

Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

August 27, 2026 | prnewswire.com

Kazia Therapeutics ADR (KZIA) Stock Forecast & Price Target

August 9, 2026 | investing.com

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

July 28, 2026 | globenewswire.com

Kazia Therapeutics ADR Stock Price History

June 17, 2026 | investing.com

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

June 2, 2026 | prnewswire.com

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

May 26, 2026 | prnewswire.com

Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst

April 30, 2026 | seekingalpha.com

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

April 15, 2026 | prnewswire.com

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

April 13, 2026 | prnewswire.com

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

January 30, 2026 | prnewswire.com

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

January 27, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KZIA, CAPR, EIKN, and EBS Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$6.59 -0.29 (-4.22%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$6.45 -0.14 (-2.12%)

As of 05:46 AM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Emergent Biosolutions NYSE:EBS

$6.90 -0.02 (-0.22%)

Closing price 10/14/2026 03:59 PM Eastern

Extended Trading

$6.85 -0.04 (-0.65%)

As of 04:51 AM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Eikon Therapeutics NASDAQ:EIKN

$7.01 +0.29 (+4.32%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$7.00 0.00 (-0.07%)

As of 10/14/2026 07:30 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

Novogen NASDAQ:KZIA

$6.79 -1.25 (-15.55%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$6.96 +0.17 (+2.49%)

As of 04:09 AM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZIA, CAPR, EIKN, and EBS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZIA, CAPR, EIKN, and EBS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZIA, CAPR, EIKN, and EBS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KZIA, CAPR, EIKN, and EBS Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Emergent Biosolutions NYSE:EBS

Eikon Therapeutics NASDAQ:EIKN

Novogen NASDAQ:KZIA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZIA, CAPR, EIKN, and EBS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZIA, CAPR, EIKN, and EBS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZIA, CAPR, EIKN, and EBS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KZIA, CAPR, EIKN, and EBS Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Emergent Biosolutions NYSE:EBS

Eikon Therapeutics NASDAQ:EIKN

Novogen NASDAQ:KZIA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools